Shanghai Rendu Biotechnology Co. Ltd. A
Shanghai Rendu Biotechnology Co., Ltd. engages in the research, development, production, and sales of RNA molecular diagnostic technology and products. It offers products in the areas of reproductive health, bloodborne infections, respiratory infections, enterovirus infections, cancer early detection, and other areas; and AutoSAT, SuperSAT, and ultrasonic homogenizer. The company was founded in 2… Read more
Shanghai Rendu Biotechnology Co. Ltd. A (688193) - Total Liabilities
Latest total liabilities as of June 2025: CN¥74.29 Million CNY
Based on the latest financial reports, Shanghai Rendu Biotechnology Co. Ltd. A (688193) has total liabilities worth CN¥74.29 Million CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shanghai Rendu Biotechnology Co. Ltd. A - Total Liabilities Trend (2019–2024)
This chart illustrates how Shanghai Rendu Biotechnology Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Shanghai Rendu Biotechnology Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Shanghai Rendu Biotechnology Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Audix Corp
TW:2459
|
Taiwan | NT$3.14 Billion |
|
PrimeEnergy Corporation
NASDAQ:PNRG
|
USA | $118.23 Million |
|
Vadilal Industries Limited
NSE:VADILALIND
|
India | ₹3.70 Billion |
|
Federal Corp
TW:2102
|
Taiwan | NT$6.89 Billion |
|
Cogstate Ltd
AU:CGS
|
Australia | AU$16.88 Million |
|
Yeal Electric Co.Ltd
SHE:300923
|
China | CN¥146.43 Million |
|
Sichuan Langsha Holding Ltd
SHG:600137
|
China | CN¥139.62 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Shanghai Rendu Biotechnology Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Rendu Biotechnology Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Rendu Biotechnology Co. Ltd. A (2019–2024)
The table below shows the annual total liabilities of Shanghai Rendu Biotechnology Co. Ltd. A from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥82.48 Million | -10.32% |
| 2023-12-31 | CN¥91.97 Million | -27.77% |
| 2022-12-31 | CN¥127.34 Million | +40.15% |
| 2021-12-31 | CN¥90.86 Million | -5.11% |
| 2020-12-31 | CN¥95.75 Million | +163.00% |
| 2019-12-31 | CN¥36.41 Million | -- |